These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9817516)

  • 1. Longitudinal trends in serum levels of mycobacterial secretory (30 kD) and cytoplasmic (65 kD) antigens during chemotherapy of pulmonary tuberculosis patients.
    Sethna KB; Mistry NF; Dholakia Y; Antia NH; Harboe M
    Scand J Infect Dis; 1998; 30(4):363-9. PubMed ID: 9817516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of circulating antibodies, immune complex and specific antibody-secreting cells in tuberculosis patients during 6 months of antimicrobial therapy.
    Sousa AO; Wargnier A; Poinsignon Y; Simonney N; Gerber F; Lavergne F; Herrmann JL; Lagrange PH
    Tuber Lung Dis; 2000; 80(1):27-33. PubMed ID: 10897381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of chemotherapy on the care of patients with tuberculosis.
    Johnston RF; Wildrick KH
    Am Rev Respir Dis; 1974 Jun; 109(6):636-64. PubMed ID: 4209115
    [No Abstract]   [Full Text] [Related]  

  • 4. [Myrin P in the combined treatment of tuberculosis].
    Sokolova GB; Semenova OV; Bogadel'nikova IV; Kunichan AD; Zeliger LR; Elistratova NA
    Antibiot Khimioter; 2002; 47(6):22-7. PubMed ID: 12422644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic mechanisms of chemotherapy.
    Mitchison DA
    Chest; 1979 Dec; 76(6 Suppl):771-81. PubMed ID: 92392
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of tuberculosis. The Mitchell lecture 1979.
    Mitchison DA
    J R Coll Physicians Lond; 1980 Apr; 14(2):91-5, 98-9. PubMed ID: 6767845
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success.
    Cowie RL; Langton ME; Escreet BC
    S Afr Med J; 1985 Dec; 68(12):879-80. PubMed ID: 4071345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of tuberculosis].
    Ben Amar J; Dhahri B; Aouina H; Azzabi S; Baccar MA; El Gharbi L; Bouacha H
    Rev Pneumol Clin; 2015; 71(2-3):122-9. PubMed ID: 25434510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
    Mourik BC; de Knegt GJ; Verbon A; Mouton JW; Bax HI; de Steenwinkel JEM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739784
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms].
    Sokolova GB; Koriakin VA; Khalbaeva IV; Elistratova NA; Ziia AV
    Probl Tuberk; 1993; (5):21-3. PubMed ID: 8295879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
    Ige OM; Bakare NA; Onadeko BO
    Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction aspects of antimycobacterial drugs in the chemotherapy of tuberculosis. I. Role of individual antituberculous drugs in drug regimens used in the chemotherapy of human tuberculosis.
    Trnka L; Tousek J
    Chemotherapy; 1974; 20(3):165-76. PubMed ID: 4136827
    [No Abstract]   [Full Text] [Related]  

  • 14. Paradoxical worsening of tuberculosis after anti-TB therapy in a kidney transplant recipient.
    Asano T; Kawamoto H; Asakuma J; Tanimoto T; Kobayashi H; Hayakawa M
    Transplant Proc; 2000 Nov; 32(7):1960-2. PubMed ID: 11120020
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of mycobacterial antigens and antibodies in circulating immune complexes from pulmonary tuberculosis.
    Raja A; Narayanan PR; Mathew R; Prabhakar R
    J Lab Clin Med; 1995 May; 125(5):581-7. PubMed ID: 7738424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
    Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA
    S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for tuberculosis today.
    Stead WW; Dutt AK
    Am Rev Respir Dis; 1982 Mar; 125(3 Pt 2):94-101. PubMed ID: 7041725
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    Mitchison DA; Nunn AJ
    Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antituberculosis agents.
    Goldberger MJ
    Med Clin North Am; 1988 May; 72(3):661-8. PubMed ID: 3280912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.